3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
3
Oropharyngeal Neoplasms
3
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage III Lung Non-Small Cell Cancer AJCC v7
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Fluorodeoxyglucose F18
×
90 days
×
Clear all
No trials found.